AstraZeneca to start new Brilinta trial, wins American College of Cardiology Foundation endorsement
This article was originally published in Scrip
Executive Summary
AstraZeneca's Brilinta/Brilique (ticagrelor) has won a class 1 recommendation from the American College of Cardiology Foundation (ACCF) and American Heart Foundation (AHF) for patients with Unstable Angina or non-ST-Elevation Myocardial Infarction.